Maehara Akiko, Patel Neil S, Harrison Louis B, Weissman Neil J, Bui Anh B, Kim Han-Soo, Ajani Andrew E, Castagna Marco T, McMillan Taya L, Yang Nathan, Chan Rosanna, Pisch Julliana, Quan Harry, Chiu-Tsao Sou-Tung, Waksman Ron, Mintz Gary S
Cardiovascular Research Institute, Washington Hospital Center, Washington DC 20010, USA.
J Am Coll Cardiol. 2002 Jun 19;39(12):1937-42. doi: 10.1016/s0735-1097(02)01880-6.
The goal of this study was to use serial (postirradiation and follow-up) volumetric intravascular ultrasound (IVUS): 1) to evaluate the actual distribution of gamma radiation in human in-stent restenosis (ISR) lesions, and 2) to analyze the relationship between neointimal regrowth and the delivered radiation dose.
The relationship between the neointimal regrowth and delivered dose during the treatment of ISR remains unknown.
We analyzed 20 actively (gamma emitter) treated, native artery ISR patients from the Washington Radiation for In-Stent restenosis Trial (WRIST) that met the following criteria: on both postirradiation and six-month follow-up IVUS imaging, > or =80% of the external elastic membrane circumference could be identified throughout the treated length including the lesion and proximal and distal reference segments. Intravascular ultrasound images were digitized every 1 mm. Proximal and distal reference and stented segment luminal and adventitial contours were imported and reconstructed. The source was placed circumferentially at the site of the IVUS catheter and longitudinally according to the relationship between the radioactive seeds and stent edges. Using Monte Carlo simulations, dose volume histograms for the adventitia and intima were calculated. The relationship between the neointimal regrowth and calculated doses were evaluated.
There was large dose heterogeneity at both the intimal and adventitial levels. Most of the sites (93%) received >4 Gy at the adventitia, and all of the sites received >4 Gy at the intima. There was no relationship between neointimal regrowth and radiation dose.
Although there may be large dose heterogeneity, gamma irradiation (using a fixed dose prescription) appears to deliver a sufficient dose to prevent neointimal regrowth.
本研究的目的是使用系列(照射后及随访)血管内超声(IVUS):1)评估γ射线在人体支架内再狭窄(ISR)病变中的实际分布,以及2)分析新生内膜增生与所给予辐射剂量之间的关系。
ISR治疗期间新生内膜增生与所给予剂量之间的关系尚不清楚。
我们分析了来自华盛顿支架内再狭窄放射治疗试验(WRIST)的20例接受积极(γ射线源)治疗的原位动脉ISR患者,这些患者符合以下标准:在照射后及六个月随访IVUS成像中,在包括病变及近端和远端参考节段的整个治疗长度内,>或=80%的外弹力膜周长可被识别。血管内超声图像每1毫米进行数字化处理。导入并重建近端和远端参考节段以及支架节段的管腔和外膜轮廓。根据放射性种子与支架边缘的关系,将源沿圆周放置在IVUS导管位置,并沿纵向放置。使用蒙特卡罗模拟,计算外膜和内膜的剂量体积直方图。评估新生内膜增生与计算剂量之间的关系。
在内膜和外膜水平均存在较大的剂量异质性。大多数部位(93%)在外膜接受>4 Gy的剂量,所有部位在内膜接受>4 Gy的剂量。新生内膜增生与辐射剂量之间无相关性。
尽管可能存在较大的剂量异质性,但γ射线照射(使用固定剂量处方)似乎能提供足够的剂量来预防新生内膜增生。